Gastrointestinal Cancers

Here’s a look back at the therapies for solid cancers that gained FDA approval this summer.

A phase 3 trial shows that zolbetuximab improved survival in patients with advanced gastric or gastroesophageal junction cancer.

A majority of women with a history of colorectal cancer experience long-term gastrointestinal symptoms, which may be associated with psychological distress, according to recent research.

We recently asked our audience of patients, survivors and caregivers about the ongoing cisplatin and carboplatin shortage. Here’s what they had to say.

Larger liver resections do not always improve survival in patients with gallbladder cancer, recent research showed.

Fruquintinib improved overall survival compared with placebo in patients with refractory metastatic colorectal cancer.

If the FDA approves zolbetuximab, this would mark the first CLDN18.2-targeting monoclonal antibody to treat patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Patients with advanced cancers who live in states that expanded Medicaid were more likely to receive early palliative care, although utilization remains low in the U.S.

Patients 60 years and older with gastrointestinal cancers who reported inadequate emotional support were more likely to have poorer physical and mental quality of life, although no effect was observed in overall survival.

From country music star, Toby Keith, providing an update on his cancer to the Duchess of York announcing her diagnosis, here’s what’s happening in the oncology space this week.

Taking five or more medications increased the risk of death, hospitalizations and ER visits in elderly patients with colorectal cancer.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

Patients with locally advanced rectal cancer treated with FOLFOX before surgery had similar outcomes and side effect profiles to those treated with presurgical pelvic chemoradiation.

The Food and Drug Administration granted a priority review for fruquintinib for patients with pretreated metastatic colorectal cancer.

States that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.

The drug combination of Lonsurf plus Avastin improved survival in patients with pretreated, metastatic, refractory colorectal cancer, according to recently published study findings.

After being no evidence of disease for about a year and a half, I am now fearing that I’m not fearing enough.

Tislelizumab was found to improve overall survival among patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

From composer Ryuichi Sakamoto’s death to the “King of Chemo” cycling across the United States to raise funds for mental health and cancer charities, here’s what’s happening in the oncology space this week.

If approved by the FDA, Keytruda plus chemotherapy could provide a frontline therapy for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Researchers conducting the VISTA-101 study will assess the safety and efficacy of KVA12123 alone and with Keytruda, in addition to determining the recommended dose of the therapy.

The Food and Drug Administration approved Keytruda for adult and pediatric patients with previously treated unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.

From Sam Neill announcing his cancer diagnosis to Martina Navratilova stating that she is now cancer-free, here’s what’s happening in the oncology space this week.

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

Many well-meaning people wanted to hug me after hearing of my rectal cancer diagnosis, but I’m not a very touchy person. So, loved ones supported me in other ways.

I’ve had three colonoscopies within five years and am still colorectal cancer-free.

The phase 2 DESTINY-PanTumor02 trial included patients with HER2-expressing solid tumors such as bladder, pancreatic and rare tumors.

“In the poker game of life, if you’re dealt a bad set of cards, the best you can do is play them as well as you can,” a cancer survivor said.

Positive results have emerged from a trial testing PIPAC, a procedure used for appendiceal, ovarian, gastric and colon cancers that works by spraying chemotherapy directly onto tumors.

From a contestant on “Queer Eye” dying of cancer to a string of brain cancers in former Philadelphia Phillies players, here’s what’s happening in the oncology space this week.